National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Fremanezumab is indicated for prophylaxis of migraine in adults who have at least four migraine days per month.


NCPE Assessment Process Complete
Rapid review commissioned 12/03/2019
Rapid review completed 17/04/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fremanezumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.